title: What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.
abstract: Summary.  Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Both of these concerns are of particular relevance in Pakistan.
authors.affiliation: Division of Gastroenterology, The Aga Khan University, Karachi 75350, Pakistan. furqaan@hotmail.com
authors.forename: F
authors.initials: F
authors.lastname: Ahmed
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics*; D003906:Developing Countries; D005838:Genotype; D006297:Health Services Accessibility; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics* / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage / Q000191:economics*; D010154:Pakistan / Q000453:epidemiology; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline